Samlyn Capital’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Samlyn Capital’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-78,672	Closed	-$11.1M	–	199
2021 Q2	$11.1M	Buy	+78,672	New	+$8.88M	0.16%	81
2020 Q1	–	Sell	-68,699	Closed	-$14M	–	129
2019 Q4	$14M	Buy	68,699 +2,725	+4%	+$497K	0.29%	72
2019 Q3	$5.3M	Buy	+65,974	New	+$5.6M	0.13%	86

Other funds holding RETA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DFO

Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Samlyn Capital's RETA Position: Q3 2021 in Review

Samlyn Capital sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2021, closing a stake of 78,672 shares — an estimated $11.1M sold.

Samlyn Capital first reported a position in RETA in Q3 2019 and held it in 3 quarters. The position peaked at $14M in Q4 2019. 181 funds tracked by Wall St. Rank hold RETA as of Q3 2021.

Samlyn Capital reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2021 after selling out during the quarter.
Samlyn Capital sold 78,672 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2021, an estimated $11.1M.
Samlyn Capital first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2019 and held it in 3 quarters.
Samlyn Capital's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $14M in Q4 2019.
181 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2021.

Based on Samlyn Capital's 13F filing for Q3 2021, filed 15 Nov 2021.